ICON Public Limited (NASDAQ:ICLR) Given Average Recommendation of “Buy” by Brokerages

ICON Public Limited (NASDAQ:ICLRGet Rating) has been given an average recommendation of “Buy” by the twelve ratings firms that are covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $282.11.

ICLR has been the subject of several analyst reports. TheStreet downgraded ICON Public from a “b-” rating to a “c” rating in a research note on Thursday, March 10th. StockNews.com initiated coverage on ICON Public in a research note on Thursday, March 31st. They set a “hold” rating for the company. Barclays reduced their price objective on ICON Public from $285.00 to $255.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 23rd. Wells Fargo & Company downgraded ICON Public from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $280.00 to $250.00 in a research note on Monday, April 25th. Finally, Mizuho reduced their price objective on ICON Public from $315.00 to $272.00 and set a “buy” rating for the company in a research note on Monday, March 7th.

NASDAQ:ICLR opened at $228.58 on Tuesday. The stock has a 50-day simple moving average of $236.38 and a 200-day simple moving average of $261.40. The stock has a market cap of $18.60 billion, a P/E ratio of 91.80, a P/E/G ratio of 1.22 and a beta of 0.98. ICON Public has a 1 year low of $204.80 and a 1 year high of $313.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.19 and a current ratio of 1.19.

ICON Public (NASDAQ:ICLRGet Rating) last posted its earnings results on Wednesday, April 27th. The medical research company reported $2.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.48 by $0.28. ICON Public had a return on equity of 12.30% and a net margin of 2.58%. During the same period in the prior year, the company posted $2.06 earnings per share. On average, equities research analysts predict that ICON Public will post 10.71 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Amundi Pioneer Asset Management Inc. grew its holdings in shares of ICON Public by 2.1% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 24,400 shares of the medical research company’s stock worth $3,332,000 after acquiring an additional 500 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of ICON Public by 65.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 142,020 shares of the medical research company’s stock worth $37,520,000 after acquiring an additional 56,023 shares during the period. TimesSquare Capital Management LLC grew its holdings in shares of ICON Public by 11,175.1% in the 3rd quarter. TimesSquare Capital Management LLC now owns 228,320 shares of the medical research company’s stock worth $59,824,000 after acquiring an additional 226,295 shares during the period. We Are One Seven LLC grew its holdings in shares of ICON Public by 14.6% in the 3rd quarter. We Are One Seven LLC now owns 7,591 shares of the medical research company’s stock worth $978,000 after acquiring an additional 969 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in shares of ICON Public by 1,443.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,389 shares of the medical research company’s stock worth $336,000 after acquiring an additional 1,299 shares during the period. 89.41% of the stock is owned by institutional investors and hedge funds.

ICON Public Company Profile (Get Rating)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Stories

Analyst Recommendations for ICON Public (NASDAQ:ICLR)

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.